<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937664</url>
  </required_header>
  <id_info>
    <org_study_id>D1040C00008</org_study_id>
    <nct_id>NCT00937664</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability &amp; Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to find out what the maximum tolerated dose is for an
      experimental drug called AZD7762 when given with the approved drug gemcitabine based on the
      side effects experienced by patients that receive both drugs.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination of the study was made after a full review of program data and assessment of the
    current risk-benefit profile.
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 3.0), laboratory values, vital sign measurements, cardiac markers, ECG, Echocardiogram</measure>
    <time_frame>Laboratory values weekly for all treatment cycles, and the other variables weekly for Cycle 0-1, then every cycle (3-4 weeks) from Cycle 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of AZD7762 when administered alone and in combination with gemcitabine</measure>
    <time_frame>According to protocol specified schedule, the number of PK samples collected during Cycle 0 and Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of AZD7762 when administered in combination with gemcitabine by assessment of Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Every 2-3 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>AZD7762 + gemcitabine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>AZD7762 administered alone and in combination with gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7762</intervention_name>
    <description>solution, intravenous, weekly</description>
    <arm_group_label>AZD7762 + gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>intravenous, weekly</description>
    <arm_group_label>AZD7762 + gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients with advanced solid tumors for which standard treatment does not
             exist or is no longer effective.

          -  Must be suitable for treatment with gemcitabine

          -  Relatively good overall health other than cancer

        Exclusion Criteria:

          -  Poor bone marrow function (not producing enough blood cells).

          -  Poor liver or kidney function.

          -  Serious heart conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Langmuir, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takashi Seto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital Organization Kyushu Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minami-ku</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>February 4, 2011</last_update_submitted>
  <last_update_submitted_qc>February 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>cancer</keyword>
  <keyword>solid tumors</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>dose escalation</keyword>
  <keyword>combination treatment</keyword>
  <keyword>CHK inhibitor</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

